Interest groups Page

Transparency Portal Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure Access...

Dades i indicadors Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2 Blog Post

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.

 

 

Moirai Biodesign developes a diagnostic kit for the detection of sepsis in three hours Blog Post

Moirai Biodesign, a biotech start-up based in the Barcelona Science Park, has developed a prototype ‘kit’ based on biosensors that analyzes a blood sample and identifiesthe most important sepsis-causing pathogens and their associated antibiotic resistances, at the point of care and directly from the patient’s blood, in just three hours, a process that usually requires up to 5 days of analysis in the laboratory. The company has just received a €75,000 grant through the Startup Capital financing line from ACCIÓ to  to set about the activities derived from the execution of the initial business plan. Its objective is to market this device in hospitals, once the validation phase is completed.The kit will allow identification 

Ernest Giralt, first IRB Barcelona Emeritus Professor Blog Post

Ernest Giralt Lledó is retiring after 15 years at the Institute for Research in Biomedicine (IRB Barcelona), where he has played a key institutional and scientific role. Dr Giralt, today an international reference for science of excellence, will continue to be linked to Institute as an Emeritus Professor. This appointment will allow him to share his guidance and expertise with the current community of scientists.

 

Scott Boyer joins Chemotargets as new CEO Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. With the new incorporation, the company, based in the Barcelona Science Park, consolidates its transition from a software business to an AI-driven biotech company.

 

La Fundació PCB Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...

The Barcelona Science Park is committed to becoming Catalonia’s MedTech company hub Blog Post

The Barcelona Science Park (PCB), a Spain’s leading scientific, technological and business innovation hub in the life sciences field, aims to embark on a new phase of growth, offering more than 1,200 square metres of office space, particularly to companies in the MedTech sector. To promote this ecosystem, it has signed an alliance with GENESIS Biomed. This consultancy firm, based in PCB, has raised more than 60 million euros for its clients since it was founded in May 2017 by Josep Lluis Falcó.

 

The CNAG-CRG participates in a European project to improve medical assistance through interceptive medicine Blog Post

Scientists from the Centro Nacional de Análisis Genómico (CNAG-CRG), based in Barcelona Science Park and integrated to the Centre for Genomic Regulation (CRG) unites with hundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united to revolutionize healthcare on the frame of LifeTime initiative. They are participating in two publications: a perspective article in the journal Nature and the LifeTime Strategic Research Agenda. They are now presenting how to improve leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.

 

IBEC and IRB Barcelona researchers receive funding from “La Caixa” for biomedical research Blog Post

Researchers from the Institute of Bioengineering of Catalonia (IBEC) and the Barcelona Institute for Biomedical Research (IRB) -based in the Barcelona Science Park- are part of the winning projects of the third Call for Applications Health Research Projects organized by “La Caixa ” Foundation, which this year allocates 18 million euros to 25 biomedical projects to tackle those diseases with the greatest global impact, such as cardiovascular, neurological, infectious and oncological.